S

ST Pharm Co Ltd
KOSDAQ:237690

Watchlist Manager
ST Pharm Co Ltd
KOSDAQ:237690
Watchlist
Price: 83 200 KRW -2.92% Market Closed
Market Cap: 1.7T KRW
Have any thoughts about
ST Pharm Co Ltd?
Write Note

ST Pharm Co Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ST Pharm Co Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
S
ST Pharm Co Ltd
KOSDAQ:237690
Cash from Operating Activities
â‚©53.1B
CAGR 3-Years
377%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Samsung Biologics Co Ltd
KRX:207940
Cash from Operating Activities
â‚©1.7T
CAGR 3-Years
188%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
K
Knotus Co Ltd
KOSDAQ:278650
Cash from Operating Activities
â‚©5.2B
CAGR 3-Years
-23%
CAGR 5-Years
9%
CAGR 10-Years
N/A
F
FutureChem Co Ltd
KOSDAQ:220100
Cash from Operating Activities
-â‚©2.5B
CAGR 3-Years
-76%
CAGR 5-Years
9%
CAGR 10-Years
N/A
L
LegoChem Biosciences Inc
KOSDAQ:141080
Cash from Operating Activities
â‚©46.7B
CAGR 3-Years
N/A
CAGR 5-Years
25%
CAGR 10-Years
N/A
C
Cellivery Therapeutics Inc
KOSDAQ:268600
Cash from Operating Activities
-â‚©533.9m
CAGR 3-Years
68%
CAGR 5-Years
42%
CAGR 10-Years
N/A
No Stocks Found

ST Pharm Co Ltd
Glance View

Market Cap
1.6T KRW
Industry
Life Sciences Tools & Services

ST Pharm Co., Ltd. develops and manufactures pharmaceutical products. The company is headquartered in Siheung, Gyeonggi-Do. The company went IPO on 2016-06-23. is a Korea-based company principally engaged in manufacture of pharmaceutical products. The firm's products mainly consist of generic active pharmaceutical ingredients (APIs), such as tipepidine hibenzate, doxifluridine, clopidogrel bisulfate, voriconazole and new medicine APIs, such as small molecule APIs. The firm distributes its products within domestic market and to overseas markets.

Intrinsic Value
97 768.06 KRW
Undervaluation 15%
Intrinsic Value
Price
S

See Also

What is ST Pharm Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
53.1B KRW

Based on the financial report for Sep 30, 2024, ST Pharm Co Ltd's Cash from Operating Activities amounts to 53.1B KRW.

What is ST Pharm Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
377%

Over the last year, the Cash from Operating Activities growth was 571%. The average annual Cash from Operating Activities growth rates for ST Pharm Co Ltd have been 377% over the past three years .

Back to Top